National Science Foundation

Eascra Biotech specializes in developing DNA-inspired, Janus base nanomaterials for targeted drug delivery. Their platform, based on three generations of DNA nanotubes, is designed to effectively penetrate and treat hard-to-reach tissues like articular cartilage, the central nervous system, and solid tumors. These nanomaterials can encapsulate and stabilize various therapeutic agents, including mRNA, siRNA, proteins, and gene-editing tools, at room temperature, enhancing their efficacy and reducing systemic exposure.

Amphix Bio is engaged in the development of advanced therapeutic materials aimed at regenerative medicine. The company specializes in creating nanofiber materials that replicate the structure and dynamic characteristics of human tissues. By integrating biological signals, these materials instruct cells to activate regenerative processes. Amphix Bio's innovations enable the development of therapies designed to repair a variety of tissues, including bone, cartilage, muscle, cardiovascular tissues, and the brain and spinal cord. The promising results observed in both preclinical and clinical trials highlight the potential of Amphix Bio's approach in transforming therapeutic applications in medicine.

Eradivir is a biotech company established in 2020 and based in West Lafayette, Indiana. The company focuses on developing a novel bispecific immunotherapy platform aimed at combating the virus responsible for COVID-19. Eradivir's approach involves creating non-immunological targeting agents that possess high specificity and avidity for a unique domain of the spike protein found on various coronaviruses. This innovation enables the effective elimination of both free viruses and virus-infected cells, even during advanced stages of infection, thereby empowering patients' immune systems to address viral challenges more efficiently.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

The Wistar Institute is the first independent institution in the United States dedicated to medical research and training, recognized for its significant contributions to biomedical science. Originally established as an anatomical teaching museum, it has transformed into a leading center for basic biomedical research and was designated a National Cancer Institute Cancer Center in 1972. The institute specializes in research areas including immunology, infectious diseases, and vaccine development. Its groundbreaking discoveries have facilitated the creation of vaccines for diseases such as rabies, rubella, and rotavirus, as well as the identification of genes linked to various cancers, including breast, lung, and prostate cancer. Additionally, Wistar has played a crucial role in advancing monoclonal antibodies and other vital research technologies, fostering a collaborative environment aimed at addressing critical health challenges.

MelliCell is focused on combating chronic diseases through innovative tissue engineering technology, specifically targeting fat cells as a source of therapeutic adipokines. Their platform enables the conversion of human stem cells into large, mature fat cells, which can be used to develop drug therapies aimed at reducing fat mass while preserving lean mass. This unique approach is designed to address conditions such as obesity, diabetes, aging, oncology, and inflammation. MelliCell's team has garnered recognition through awards and partnerships with leading biopharma companies, validating their technology. By advancing oral small molecules that shrink fat cells, MelliCell aims to enhance health outcomes and improve the quality of life for individuals affected by these diseases.

Theromics Inc. is a biotechnology company focused on developing innovative cell therapies, particularly in the field of thermal ablation for cancer treatment. Founded in 2016 and based in West Bridgewater, Massachusetts, the company has created HeatSYNC Gel, a biopolymer thermal accelerant designed to enhance the effectiveness of microwave and radiofrequency ablation procedures. This gel improves the delivery and absorption of thermal energy in soft tissue and bone, optimizing the ablation zone's shape and volume. By increasing local tissue electrical conductivity, HeatSYNC Gel helps to prevent heat loss due to blood flow, allowing for more precise targeting of tumors and protecting surrounding healthy tissue. The gel can be administered through various methods, including syringe, laparoscope, and bronchoscope, and is intended to improve the overall efficacy of thermal ablation therapies while enabling personalized treatment approaches.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

Astria Biosciences, based in Pittsburgh, specializes in developing innovative diagnostic and therapeutic solutions for cerebrovascular diseases. The company focuses on addressing neurosurgical challenges through molecular biology, advanced analytics, and small-molecule inhibitors, aiming to provide non-surgical alternatives for neurovascular conditions where surgery is currently the primary option.

CerFlux specializes in personalized medicine technology designed to enhance cancer treatment by matching patients with the most effective therapies for their specific tumors. The company's innovative tests identify the most efficient and effective treatment options for individual patients, allowing healthcare practitioners to distinguish optimal therapies from less effective ones. This approach aims to improve patient outcomes and quality of life while minimizing the time, pain, and costs associated with cancer treatment. By focusing on personalized treatment efficacy, CerFlux contributes to a more tailored and effective healthcare experience for those battling cancer.

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for various debilitating conditions. The company employs a modular approach to research and development, utilizing established technologies in innovative ways to address well-understood disease mechanisms. By focusing on clinically validated molecules and targeted treatment strategies, Remedium Bio aims to create effective therapies for conditions within rheumatology, endocrinology, and neurology. Its pipeline includes promising gene therapy candidates designed to tackle a wide range of diseases, including immune and age-related disorders.

Sharper Sense is a company focused on wearable neurotechnology designed to enhance sensory acuity, including vision, hearing, and touch. The firm has developed a neuromodulation patch that employs comfortable, noninvasive electrical stimulation to improve sensory processing. This technology has both clinical and commercial applications, particularly in treating sensory processing disorders and sensory loss. By enhancing performance and safety, Sharper Sense aims to provide users with a clearer and more accurate perception of their surroundings.

BioSuperior Technology is a preclinical biotherapeutics company specializing in lung disease treatments. It has developed a novel, synthetic pulmonary surfactant prototype called BioSurf, which directly treats lung conditions and delivers potent drugs to restore normal lung function. This technology has the potential to repair damaged lung tissue and may also treat other microvasculature-related illnesses like hemorrhagic stroke and chronic kidney disease.

Bespoke Biotherapeutics provides an effective natural immune response and overcomes the limitations of currently approved immunotherapies against cancer by inventing novel, customised living drugs called engineered B-cell therapeutics. They offer customised B-cell sourcing, isolation, activation, culture expansion, and non-viral genetic engineering methodologies uniquely suited to optimise commercial B-cell products for infusion.

Tiny Cargo specializes in a unique drug delivery system utilizing non-immunogenic bovine milk-derived exosomes. This innovative approach allows for the effective oral or intravenous administration of potent therapeutics. The company focuses on delivering treatments for various serious health conditions, including ischemic heart disease, gastrointestinal radiation disease, and glioblastoma multiforme, among others. By leveraging its technology, Tiny Cargo aims to enhance the delivery of peptide drugs, making it applicable to a wide range of current peptide therapeutics and improving patient outcomes in the treatment of neurological and other pathologies.

OncoSTING LLC, founded in 2018 and based in Baltimore, Maryland, specializes in developing innovative therapies for bladder cancer. The company's approach integrates the established efficacy of BCG immunotherapy with a novel delivery system for potent STING agonists, which aims to enhance treatment effectiveness while minimizing the adverse effects typically associated with traditional BCG therapy. By focusing on this combination, OncoSTING seeks to provide a more effective and safer treatment option for patients suffering from bladder cancer.

Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

Oxalo Therapeutics is focused on developing innovative drug therapies aimed at treating rare kidney diseases and preventing recurring kidney stones. The company specifically targets primary hyperoxaluria and other oxalate-related pathologies through a novel approach that utilizes a gut bacterium to facilitate the safe removal of oxalate from the body. By mimicking natural mechanisms, Oxalo Therapeutics seeks to provide effective treatment options for patients suffering from conditions associated with high levels of oxalate, thereby improving their quality of life and reducing the incidence of kidney stone recurrence. The company's expertise in the microbiome and translational research underpins its commitment to advancing early-stage technology in the field of kidney health.

Simmbion specializes in innovative therapeutic solutions by utilizing symbionts to manufacture therapeutic agents directly within the human body, effectively transforming it into a living pharmacy. This technology aims to eliminate the challenges associated with traditional therapy manufacturing, such as the need for complex production processes, repeated injections, and temperature-sensitive storage. By providing a single injection that lasts up to 12 weeks, Simmbion's approach addresses supply chain disruptions and enhances affordability and accessibility of cell therapies for diverse patient populations. Their adaptable and universally immune compatible systems focus on delivering biological drugs directly in vivo, supporting a patient-centric and outcome-driven healthcare model while minimizing the risks of infections and immune rejection.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

Iaso Therapeutics, founded in 2018 and based in East Lansing, Michigan, is a biotechnology company focused on developing vaccines aimed at improving human health and treating infectious diseases. The company’s platform is dedicated to creating vaccines for serious illnesses, including smallpox, yellow fever, and tetanus. By providing healthcare professionals with innovative technologies, Iaso Therapeutics seeks to enhance public health outcomes and address critical health challenges.

Hypersound Medical is focused on developing non-invasive neuromodulatory devices that utilize neurostimulation techniques to address chronic pain conditions. The company's products employ microwave energy to stimulate nerve cells, offering pain relief for various ailments, including arthritis, back pain, and neuropathic pain. By enhancing pain management, Hypersound Medical aims to improve patient function and reduce reliance on pain medication. Their approach encompasses various stimulation methods, such as peripheral nerve stimulation and spinal cord stimulation, positioning the company as a key player in the field of pain relief technology.

Amphix Bio is engaged in the development of advanced therapeutic materials aimed at regenerative medicine. The company specializes in creating nanofiber materials that replicate the structure and dynamic characteristics of human tissues. By integrating biological signals, these materials instruct cells to activate regenerative processes. Amphix Bio's innovations enable the development of therapies designed to repair a variety of tissues, including bone, cartilage, muscle, cardiovascular tissues, and the brain and spinal cord. The promising results observed in both preclinical and clinical trials highlight the potential of Amphix Bio's approach in transforming therapeutic applications in medicine.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Window Therapeutics is focused on discovering and developing innovative therapeutics to meet significant unmet patient needs in cancer and other severe diseases. The company specializes in breakthrough cancer treatments designed to specifically target and penetrate diseased tissue while sparing healthy cells. Utilizing a bioinspired cylindrical design, their therapies are engineered to home in on cancer sites, enhancing their effectiveness and addressing key challenges in cancer treatment. This targeted approach aims to accelerate drug development and reduce the risks associated with traditional therapies, ultimately improving outcomes for patients facing life-threatening conditions.

Nostopharma specializes in developing treatments for pathologic bone growth, aiming to prevent rare bone diseases and minimize complications from traumatic injuries. The company offers a nanoparticle drug delivery system that addresses soft tissue trauma complications, facilitating the formation of new bone after surgeries, burns, and other traumatic incidents. By enhancing the recovery process, Nostopharma's innovative approach supports healthcare providers in improving clinical outcomes for patients undergoing surgical procedures related to post-traumatic injuries. Additionally, the company's efforts contribute to reducing rehabilitation costs for society.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

Auctus Biologics is a pre-clinical biotechnology company focused on developing antibody mimetics for therapeutic and diagnostic uses. By engineering a ribose-binding protein, the company aims to create a scaffold that binds clinical targets with an affinity comparable to monoclonal antibodies while addressing the limitations associated with traditional antibodies. These limitations include instability and the need for costly cold-chain logistics, which can hinder their effectiveness in extreme environments such as the gastrointestinal tract. Auctus Biologics' innovative approach allows for treatments that are not only more resilient, capable of withstanding conditions like repeated boiling cycles, but also more accessible and cost-effective for patients. This advancement may significantly enhance the delivery of advanced medical therapies.

Reselute is a medical technology company focused on addressing orthopedic implant-related infections. The company specializes in designing, developing, and validating innovative orthopedic spacers that serve as a treatment solution. By leveraging advanced technologies, Reselute aims to enhance the efficiency of medical treatments and improve patient care, ultimately assisting healthcare providers in delivering timely and effective interventions for their patients.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

MBF Therapeutics, Inc. is a veterinary oncology company that specializes in developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company's product portfolio features targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing healthy tissues. Key products include MBFT-101, a combination therapy for sarcomas and lymphoma that utilizes a proprietary polyamine transport inhibitor alongside a potent inhibitor of ornithine decarboxylase, and MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human clinical trials for various advanced cancers. Additionally, MBF Therapeutics is advancing a gene-based vaccine platform aimed at improving treatments for both cancer and infectious diseases in animals, with the potential to transform veterinary medicine. The company is located in Ambler, Pennsylvania, and maintains a strategic partnership with the Lankenau Institute for Medical Research.

Vulcan Biologics is a biotechnology company based in Irvine, California, established in 2019. It specializes in the modulation of the microbiome through the use of bacteriophages, which are viruses that specifically infect bacteria without harming human cells. This innovative platform aims to achieve stable and persistent changes in the gut microbiome, facilitating the treatment of gluten-related disorders such as gluten sensitivity and celiac disease. By altering the composition of gut bacteria, Vulcan Biologics enables healthcare providers to offer targeted therapeutic solutions for individuals affected by these conditions.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Akttyva Therapeutics specializes in the development of targeted therapeutics aimed at addressing cell barrier dysfunction associated with various vascular disorders. The company leverages a deep understanding of biological pathways, along with advanced artificial intelligence and machine learning techniques, to design solutions that enhance the treatment of these conditions. Through its innovative approach, Akttyva Therapeutics seeks to provide healthcare professionals with effective tools to manage and treat disorders related to cell barriers.

Nasus Medical is focused on addressing the challenge of inadequate early treatment for chronic sinusitis through the development of a non-invasive drug-delivery device. This innovative solution allows patients to manage their condition in a non-clinical setting, minimizing the need for systemic medications, injections, or invasive procedures that often come with significant side effects or high costs. The device is designed to be rapidly effective and easily self-administered, offering a more accessible and affordable alternative for individuals suffering from chronic rhinosinusitis.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Felix Biotechnology, founded in 2019 and based in San Francisco, California, is focused on developing biotherapeutics aimed at addressing microbial challenges in human health, particularly antibiotic-resistant strains of bacteria and fungi. The company aims to accelerate the deployment of innovative treatments for infectious diseases, enabling healthcare professionals to manage these urgent health threats effectively. Through its targeted approach, Felix Biotechnology seeks to provide precise and effective solutions to combat the growing issue of antibiotic resistance.

Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.

TheraCea Pharma is a biotechnology company based in Tucson that focuses on developing precision medicine for individuals with neurological disorders. As a spin-off from the University of Arizona, the company has developed and licensed advanced radiochemistry technology that enables efficient and rapid fluorine-18 radiolabeling of biomolecules. This innovative approach supports both clinical and research applications, particularly in the context of neurological conditions. TheraCea Pharma's treatments aim to counteract dyskinesia, a side effect commonly associated with L-dopa, the standard treatment for Parkinson's disease. By providing new diagnostic agents, the company enhances medical professionals' capabilities in detecting not only neurological disorders but also cancer, thereby contributing to improved healthcare outcomes.

Kodikaz Therapeutic Solutions is focused on advancing cancer treatment by developing targeted therapies aimed at eradicating cancers while minimizing side effects. The company utilizes its innovative Zip-Code™ Technology platform, a first-in-class delivery system that facilitates cell-specific genomic transfer for both RNA and DNA applications. Rooted in discoveries from human cancers, this platform addresses the limitations associated with traditional viral delivery methods, providing a more effective and safer alternative. Kodikaz's research generates valuable in-vitro and in-vivo data across various oncological applications, including pancreatic, myeloma, and colorectal cancers, supporting the development of curative gene transfer technologies.

TRGel, founded in 2010 and located in Irvine, California, specializes in the development of glucose-based biopolymers designed to serve as an alternative to calcium alginate for encapsulation purposes. The company’s biopolymers are crafted from biocompatible materials, which encompass thermoresponsive hydrogels with adjustable gelation temperatures. These innovative biopolymers enable researchers to utilize them effectively as vehicles for drug delivery, expanding the possibilities for applications in various fields.

ZelosDx specializes in the development of blood testing products aimed at advancing research in brain health and diseases. The company provides researchers with access to proprietary technology that can be licensed and adapted for blood testing kits and automated laboratory equipment. Additionally, it offers pharmaceutical collaborators biomarker technology to support drug discovery efforts. By delivering critical data for diagnosis, monitoring, and evaluating therapeutic responses, ZelosDx facilitates significant advancements in the understanding and treatment of brain-related conditions.

Nano PharmaSolutions specializes in enhancing the bioavailability of insoluble drugs through its proprietary nanoformulation technology. The company has developed an innovative phase-transition technology platform that significantly improves the solubility of BCS 2 and BCS 4 active pharmaceutical ingredients (APIs) without the need for excipients, which are typically used in traditional processes like spray-dry dispersion and emulsification. By vaporizing the API and depositing it onto a carrier molecule, Nano PharmaSolutions enables the production of nanoparticles that can be processed into various dosage forms. Additionally, the company focuses on delivering neurodegenerative therapeutics directly to the brain via an intranasal route, facilitating a rapid onset of action and enhancing safety profiles. Their pipeline includes treatments for conditions such as Parkinson's disease, peripheral neuropathy, and substance abuse disorders, positioning Nano PharmaSolutions as a key player in the field of nanomedicine.

MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Theromics Inc. is a biotechnology company focused on developing innovative cell therapies, particularly in the field of thermal ablation for cancer treatment. Founded in 2016 and based in West Bridgewater, Massachusetts, the company has created HeatSYNC Gel, a biopolymer thermal accelerant designed to enhance the effectiveness of microwave and radiofrequency ablation procedures. This gel improves the delivery and absorption of thermal energy in soft tissue and bone, optimizing the ablation zone's shape and volume. By increasing local tissue electrical conductivity, HeatSYNC Gel helps to prevent heat loss due to blood flow, allowing for more precise targeting of tumors and protecting surrounding healthy tissue. The gel can be administered through various methods, including syringe, laparoscope, and bronchoscope, and is intended to improve the overall efficacy of thermal ablation therapies while enabling personalized treatment approaches.

SingletO2 Therapeutics is a biotechnology company founded in 2015 and based in New Providence, New Jersey. The company focuses on developing innovative treatments for periodontal disease by utilizing the unique properties of singlet oxygen. This advanced approach capitalizes on the bacteria-killing capabilities of singlet oxygen, enabling clinicians to effectively treat advanced stages of periodontal disease without the need for surgical intervention. Through its research and development efforts, SingletO2 Therapeutics aims to improve patient outcomes and transform the management of periodontal health.

Drive Therapeutics is a biotechnology company focused on enhancing treatments for retinal diseases. The company is developing therapeutics specifically aimed at addressing wet age-related macular degeneration and diabetic retinopathy, including diabetic macular edema. Through its innovative approach, Drive Therapeutics aims to provide more effective solutions for patients suffering from these serious eye conditions.

Paramita Therapeutics is a biotech company established in 2018 and based in San Diego, California. The company is dedicated to developing innovative therapeutics for cancer and infectious diseases. It specializes in efficiently transitioning new therapeutics into clinical settings using a patented, multifunctional chemical platform. This approach allows Paramita Therapeutics to create multivalent drug conjugates derived from recognized and approved molecules with established safety and toxicology profiles. By leveraging its expertise, the company aims to provide patients with access to effective cancer treatments and dual-function therapeutic and vaccine products.

ALSUS MEDICAL offers treatment for urinary stream problems that may be weak or stop and start. In some cases, it can lead to infection, bladder stones, and reduced kidney function. They offer treatments that include medication that relaxes or shrinks the prostate, surgery, and minimally invasive surgery.

Cordance Medical is a medical device company focused on developing innovative therapies for central nervous system (CNS) pathologies, including primary and metastatic cancers, Alzheimer's disease, and Parkinson's disease. The company has created a non-invasive ultrasound system that precisely opens the blood-brain barrier, allowing for targeted delivery of systemically administered drugs to specific brain regions. This low-power ultrasound technology aims to enhance diagnostic and therapeutic options for patients, providing a safe and effective means to address complex neurological conditions.

InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine. It offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular tissues. The company also offers reconstructive plastic surgeries and injectable materials.

Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.

Tacit Therapeutics is a biotechnology company focused on developing RNA-targeted treatments to address genetic diseases. Founded in 2021 and based in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative, non-immunogenic methods for repairing mutated genes. By offering a broadly applicable approach to gene modification, Tacit Therapeutics aims to provide effective solutions for genetic conditions that were previously deemed untreatable, thereby enabling advancements in the treatment of devastating diseases.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

SpheroFill is a drug delivery platform that specializes in the development of injectable tissue fillers, particularly for treating age-related atrophy in the larynx. The company utilizes a unique combination of solid, hollow, and porous-wall hollow glass microspheres mixed with biocompatible and bioactive matrices. This innovative approach enhances the delivery of active pharmaceutical ingredients (APIs) in various forms, including solids, liquids, and gases. By improving compliance through reduced dosing frequency and enabling previously impossible oral formulations, SpheroFill is positioned as a leader in advancing drug delivery technology, offering healthcare professionals enhanced devices for more effective treatments.

Midday is an app that leverages AI, sensor technology, and digital therapeutics to support women on their menopause journey using personalized insights that illuminate what is happening physically and emotionally during menopause, providing the right intervention at the right time to manage menopause symptoms and promote healthy aging.

Current Surgical is a surgical device company founded in 2020 and headquartered in Washington, DC. The company specializes in developing advanced tools aimed at the treatment of solid tumors. Its flagship product is a smart surgical needle designed for minimally invasive tumor detection and ablation. This innovative needle utilizes real-time X-ray guidance and ultrasound energy to effectively heat and destroy tumors while preserving surrounding vital organs and tissue. By enabling surgeons to target tumors located near critical anatomy, Current Surgical aims to enhance surgical precision and improve patient outcomes.

NellOne Therapeutics, Inc. is a regenerative medicine company based in Oak Ridge, Tennessee, focused on developing and commercializing protein therapeutics aimed at restoring cardiac muscle mass and function in patients recovering from myocardial infarctions and congestive heart failure. The company was established as a spin-off from the U.S. Department of Energy's Oak Ridge National Laboratory, where research on the Nell1 gene's pathway was conducted, revealing its role in the formation of critical mammalian tissues and organs. Founded by Battelle Ventures, NellOne is dedicated to translating this scientific discovery into effective clinical applications for heart recovery.

Precision Theranostics is a biotechnology company based in Baltimore, Maryland, founded in 2019. The company focuses on developing prognosis-based intervention strategies aimed at the early detection and treatment of fatal diseases. Its innovative platform is designed to estimate disease progression, particularly for respiratory diseases and age-related disorders. By creating novel diagnostics, therapeutics, and prognosis-based therapies, Precision Theranostics enables healthcare providers to deliver timely diagnoses and interventions, ultimately improving survival rates and preventing the progression of chronic and fatal conditions.

Galaxy Therapeutics provides neurovascular devices that increase the rate of curing the disease and offer easy deployment, fluoroscopic visualization, and treatment for shallow or large aneurysms, enabling patients to avail improved medical treatment.

Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

FluidForm Bio is a biotechnology company focused on creating living human tissue to enhance disease treatment. Utilizing its patented FRESH technology, the company specializes in 3D bioprinting, which enables the production of high-quality tissue that mimics real human tissue by integrating cells and proteins without additional materials. This innovative platform allows for the design and fabrication of complex tissue structures with embedded vasculature and multiple materials within a single print. Through collaborations with leading life science companies, FluidForm Bio's technology has been validated for various applications, paving the way for novel therapeutic programs in the healthcare sector. Founded in 2018 and headquartered in Waltham, Massachusetts, FluidForm Bio aims to provide better treatment options for patients through its transformational approach to tissue engineering.

Infini Fluidics develops injectable drug delivery systems intended to treat diseases such as cancer and cardiovascular disease. They provide injectable drug delivery systems at an industrial scale on a portable chip, combining microfluidics with semiconductor technology, enabling patients, healthcare providers, and facilities to get access to lifesaving drugs.

Enable Therapeutics is a biotechnology company developing a patented drug delivery platform. The company was founded in 2020 and is headquartered in Hopedale, Massachusetts.

Amberstone Biosciences specializes in the discovery of novel immunotherapies aimed at addressing unmet medical needs through advanced technologies and strategic collaborations. The company focuses on challenging therapeutic targets that require unique mechanisms of action, which traditional methods struggle to tackle. Amberstone employs a microfluidics-powered drug discovery platform, known as AmberFlow, to analyze single-cell functions within a customizable microenvironment. This innovative approach allows for a more precise understanding of immune responses, enabling the development of transformative therapeutic antibodies. The team's expertise in immuno-oncology and single-cell assay biology further enhances their capacity to create effective treatments, ultimately improving patient outcomes.

Impact Proteomics, LLC specializes in protein sample preparation, offering a range of kits and reagents designed to produce contaminant-free samples. Founded in 2017 and based in Pittsburgh, Pennsylvania, the company provides various products, including Universal Protein Extraction and Clean Kits for peptides, whole proteins, and immunoprecipitation, as well as Promtag Reversible Protein Tagging Agents and related accessories. By supplying tools for efficient protein handling, Impact Proteomics aims to enhance drug and biomarker discovery processes, allowing researchers to accelerate the development of therapeutics and diagnostics. The company's offerings are available for purchase online, reflecting its commitment to supporting the scientific community in advancing medical research.

Cobio Diagnostics is a biotechnology company based in Golden, Colorado, founded in 2016. The company specializes in developing diagnostics aimed at rapid bacterial identification and phenotypic antibiotic resistance testing. Utilizing a phage-based immunoassay, Cobio Diagnostics' technology can identify specific bacterial species and determine the most effective antibiotic treatment in under five hours. This innovative approach provides a faster and more targeted alternative to traditional diagnostic methods, allowing healthcare providers to make quicker and more informed decisions regarding antibiotic treatment for patients with bacterial infections.

NeyroblastGX is a biotechnology company established in 2020 and based in Murrieta, California, focused on developing theranostic products aimed at treating neurodegenerative and infectious diseases. The company’s product offerings include a blood-based biomarker diagnostic for Alzheimer's, genetically engineered dendritic cells designed to eliminate custom-made human organoids for drug screening, cellular toxicity assessment, and disease pathology. Additionally, NeyroblastGX develops an oral supplement intended to enhance protective immunity, providing patients with a comprehensive portfolio of diagnostics, drugs, and therapies to combat life-threatening conditions.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

VeriSIM Life, Inc. is a biotechnology company based in San Francisco, California, established in 2017. It specializes in developing disease-specific biosimulation models that utilize artificial intelligence to predict the clinical outcomes of new drugs prior to clinical trials. The company offers a range of tailored solutions designed for pre-clinical and clinical programs, all centered around its validated BIOiSIM platform, which accommodates small molecules, large molecules, and viruses. By replacing traditional animal testing with sophisticated software simulations, VeriSIM Life aims to enhance the accuracy and efficiency of drug development, ultimately contributing to increased human life expectancy and the personalization of healthcare treatments.

Florica Therapeutics, founded in 2019 and based in Livermore, California, focuses on developing exosome-based therapeutics aimed at extending lifespan and preventing age-related diseases. The company specializes in delivering drugs to the brain, offering innovative treatment alternatives for serious conditions such as leukemia and Tay-Sachs disease. By advancing these therapeutics, Florica Therapeutics seeks to improve patient outcomes and enhance the quality of life for individuals affected by terminal illnesses.

Gradient Medical, founded in 2020 and based in Raleigh, North Carolina, specializes in developing innovative interventional oncology services, specifically focused on ACE therapy. This therapy utilizes electrical pulses designed to target cancer cells and disrupt essential biological functions. By incorporating real-time sensing technology, Gradient Medical provides clinicians with enhanced control over the treatment area, which optimizes therapeutic effectiveness and reduces treatment durations. This approach enables healthcare professionals to effectively treat large, inoperable tumors located near vital structures, addressing a critical need in cancer care.

Nano RED specializes in precision delivery technologies aimed at advancing RNA and immunotherapeutics for cancer treatment. The company develops innovative immunotherapy solutions that utilize liposomes, which are injected into the bloodstream. This approach allows for the direct release of cancer therapies into tumors and their surrounding environments, while also addressing the associated toxicity within the body. Through its cutting-edge technology, Nano RED seeks to enhance the effectiveness of cancer treatments and improve patient outcomes.

FibrosIX is a biotechnology company founded in 2016 and based in East Lansing, Michigan. The company focuses on developing small-molecule therapeutics aimed at preventing lung fibrosis in cancer patients. Its drug candidates target a crucial signaling pathway involved in the progression of fibrotic diseases. By doing so, FibrosIX aims to help healthcare providers mitigate issues related to poor lung function and shortness of breath in affected patients.

NeuroDyne specializes in developing medical technology aimed at diagnosing and treating neurological diseases. The company focuses on creating devices that alleviate seizure activity in children with congenital brain disorders, adults experiencing seizures, and veterans affected by brain damage. By providing innovative solutions, NeuroDyne enables medical professionals to offer effective relief to individuals suffering from the debilitating effects of seizures.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Spirrow Therapeutics provides lung restoration to babies suffering from ARDS by using new proprietary methods. They provide polymer lung surfactant to low complexity synthesis and formulation, interface affinity exceeds competing agents, reduces alveolar surface tension, and fluid accumulation.

GRI Bio, Inc. is a clinical-stage biotechnology company based in La Jolla, California, focused on developing innovative therapies for liver disease and autoimmune disorders. The company specializes in harnessing Natural Killer T (NKT) cell-based therapies to address dysregulated immune responses associated with inflammatory and fibrotic diseases. One of its primary product candidates, GRI-0621, is an oral small molecule that inhibits type 1 NKT cells, aiming to restore immune system balance in patients with liver conditions. Additionally, GRI Bio is advancing GRI-0803, an oral agonist targeting type 2 NKT cells. Established in 2009, GRI Bio is committed to discovering and commercializing effective treatments for serious health challenges linked to immune system dysfunction.

Grit Bio is a biotechnology company founded in 2017 and based in New York, NY, focused on developing cancer therapeutics specifically aimed at pharyngeal squamous cell carcinoma. The company's innovative approach targets the increased turnover of lipid metabolism and the production of oncogenic products associated with sphingolipid metabolism. By addressing these mechanisms, Grit Bio aims to enhance the safety of cancer treatment and extend remission periods for patients.

Eradivir is a biotech company established in 2020 and based in West Lafayette, Indiana. The company focuses on developing a novel bispecific immunotherapy platform aimed at combating the virus responsible for COVID-19. Eradivir's approach involves creating non-immunological targeting agents that possess high specificity and avidity for a unique domain of the spike protein found on various coronaviruses. This innovation enables the effective elimination of both free viruses and virus-infected cells, even during advanced stages of infection, thereby empowering patients' immune systems to address viral challenges more efficiently.

Souvie Biodelivery, founded in 2018 and headquartered in Tucson, Arizona, specializes in drug delivery services aimed at niche markets. The company focuses on developing innovative drug delivery platforms utilizing nanotechnology, particularly engineered exosomes. These exosomes are designed for targeted tissue and site-specific delivery of active pharmaceutical ingredients (APIs). By enhancing biocompatibility and non-immunogenicity, Souvie Biodelivery aims to protect APIs from degradation and improve their specificity and efficacy. This approach has the potential to significantly reduce adverse drug reactions, allowing patients to avoid the side effects commonly associated with traditional drug therapies.

Progenitor MDX is engaged in developing cellular immunotherapy technologies that facilitate the creation of induced pluripotent stem cells for use in immune-oncology and engineered cell therapies. The company combines all Yamanaka factors into a single vector, enabling simple and reliable cellular reprogramming. This innovation supports the efficient production of allogeneic off-the-shelf CAR constructs derived from various cell sources. In addition to its focus on cellular immunotherapy, Progenitor MDX offers a comprehensive and customizable solution for managing COVID-19 infections, which includes providing testing results and actionable plans for infection management to support community health.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

Ernest Pharmaceuticals is a biotechnology company based in Hadley, Massachusetts, founded in 2016. The company specializes in developing innovative bacterial therapeutics aimed at treating cancer. Its unique approach involves programming bacteria to deliver intracellular macromolecules directly into tumor tissues. These engineered bacteria are motile, allowing them to actively penetrate and target metastatic diseases and inoperable tumors. Through these advancements, Ernest Pharmaceuticals aims to enhance treatment options for patients facing challenging cancer diagnoses.

Optimeos Life Sciences is a biotechnology company focused on developing advanced drug delivery systems that utilize biologics, peptides, and RNA for disease treatment. The company has created encapsulation technology that enhances the efficacy of these therapeutic agents by protecting them and ensuring their precise delivery to targeted areas within the body. This innovation addresses existing challenges in the field of biologics and peptide therapeutics, facilitating sustained release of these treatments through the use of nano-composite microparticles. By improving the delivery mechanism, Optimeos Life Sciences aims to enhance patient outcomes in the management of various diseases.

SKROOT Laboratory specializes in the development of wireless sensor systems designed for biotherapeutic process developers. The company has created a unique sensor sticker that, when applied to a reactor and paired with a reader, provides a wireless, non-invasive platform capable of continuously measuring critical parameters such as cell concentration, foaming, and temperature in upstream cell vessels and single-use bioreactors. This innovative technology enables operators to closely monitor bioprocesses, significantly reducing the risk of advancing costly conditions and accelerating the time to market for biotherapeutic products.

Think Bioscience is focused on advancing synthetic biology to enhance the design and assembly of improved medicines. The company utilizes a unique technology that encodes complex molecular objectives into microbial hosts, facilitating the identification, construction, and evolution of small molecules. This innovative approach allows medical researchers to leverage microbes in the drug discovery process, potentially leading to more effective therapeutic solutions. Through its efforts, Think Bioscience aims to transform how medicines are developed and contribute to the future of healthcare.

Saphtx is a biotechnology company based in Newark, New Jersey, founded in 2018. The company specializes in developing protein-based therapeutic strategies aimed at treating a variety of diseases. Utilizing advanced techniques such as computer-aided lead compound design and screening, natural product discovery, drug repurposing, and combination therapy, Saphtx focuses on creating innovative technologies to address health challenges. Their work includes therapies for COVID-19 and other diseases, enhancing treatment options for patients.

TEGA Therapeutics, Inc. is focused on developing glycoscience-related technologies aimed at treating life-threatening diseases. Founded in 2013 and based in La Jolla, California, the company specializes in enhancing the delivery of enzyme replacement therapies to the brain, particularly for lysosomal storage disorders. By leveraging glycoside-enhanced delivery methods, TEGA addresses significant challenges in reaching the central nervous system, thereby improving treatment outcomes. Additionally, the company produces bio-engineered heparan sulfate and heparin, which play crucial roles in various physiological processes. TEGA's mission is to improve the quality of life for patients by providing innovative solutions for unmet medical needs, utilizing rigorous scientific methods to advance the therapeutic potential of glycans in medicine.

Seven Biosciences provides drug discovery platforms for G-protein coupled receptors. The company, based in Davis, California, was founded by Grace Mizuno and Lin Tian.

Omnicyte is a biotechnology company focused on developing targeted treatments for cancer therapy. It utilizes a proprietary Immuno-Oncology Platform Technology to create recombinant targeted immunomodulators aimed at addressing unmet medical needs in oncology. The company is actively working on treatments for various cancer indications, including ovarian cancer and small cell lung cancer. By advancing its innovative platform, Omnicyte aims to enhance patient outcomes and improve quality of life for individuals affected by these challenging diseases.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. The company employs a synthetic biology approach to rapidly design and synthesize a diverse pipeline of therapeutic assets targeting cancer, autoimmune diseases, drug delivery, and gene therapy. By utilizing advanced cell engineering techniques, Jupiter Therapeutics creates customized vesicles that enhance immuno-oncology applications and gene therapy strategies. This innovative approach allows medical researchers to leverage insights gained from cell-membrane studies to improve treatments involving CAR T-cells and bi-specific antibodies.

ActivSignal, established in 2016 and based in Natick, Massachusetts, specializes in biotechnology. The company focuses on developing innovative protein profiling technologies, primarily serving the proteomics research sector. Their tools enable scientists to analyze multiple signaling pathways simultaneously, providing insights into cellular pathway activation or inhibition profiles.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.